ArticleInternational journal of clinical and experimental pathology2020
Expression of EZH2 and P53 and their correlation in ovarian cancer tissues.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer.Biomedicines · 2026Review
- Combined Assessment of EZH2 and EGFR as Potential Diagnostic Biomarkers for Epithelial Ovarian Tumors: Bioinformatics Analysis and Clinical Validation.International journal of women's health · 2026Article
- Pan-cancer analysis reveals netrin-1 receptors as potential tumor biomarkers and immune-related therapeutic targets.Scientific reports · 2025Article
- Review
- Deciphering the role of IGF2BP2 and PRMT5 in gallbladder cancer progression: insights from multi-omics analysis.British journal of cancer · 2025Article
- RGD hydrogel-loaded ADSC extracellular vesicles mitigate uranium-induced renal injury via TLR4/NF-κB pathway inhibition.Journal of nanobiotechnology · 2025Article
- Deciphering the Puzzle: Literature Insights onMicroorganisms · 2024Review
- The transcription factor ELF4 alleviates inflammatory bowel disease by activating IL1RN transcription, suppressing inflammatory TH17 cell activity, and inducing macrophage M2 polarization.Frontiers in immunology · 2023Article
- EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous researches have demonstrated that EZH2 expression is increased in many solid tumors and is closely related to the worse progression, transcriptional silence, distal metastasis, and differential inhibition of tumors. P53 can regulate many cells signaling pathways and play an important role in cell cycle, cell apoptosis, and cell senescence. However, there are few reports on the expression of EZH2 and p53 in ovarian cancer and their correlation with the ovarian cancer. The purpose is to elucidate the expression of EZH2 and p53 in ovarian cancer and to study the relationship of EZH2 and p53 with the clinical parameters of ovarian cancer. In this study, both mRNA and protein level of EZH2 in ovarian cancer group was significantly higher than that in borderline, benign, and normal group; while the mRNA and protein level of p53 was significantly lower than that in borderline, benign, and normal group. The expression of EZH2 protein was mainly located in the cytoplasm and nucleus, while mutated p53 protein was mainly located in the nucleus. Furthermore, the expression of EZH2 is closely related to the FIGO stage and histological grade of ovarian cancer. EZH2 and P53 are closely related to the occurrence of ovarian cancer. We speculate that EZH2 may promote the development of ovarian cancer by inhibiting the expression of p53, suggesting that p53 may be the target gene of EZH2.
Indexed as
Identifiers
32269682PMC7137013W3027056600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.